Beware of this loh chin stock...if not bomba need to prepare safety tools to save your life !!
DO NOT invest in HO WAH GENTING BHD for its Covid19 vaccine work.
What they are doing is to see if the polio vaccine is protective against the Covid19. I can tell everyone right now the polio vaccine is not protective against Covid19.
How do I know that?
1 - Polio is a different virus from Covid19. 100% different virus. Vaccines are very specific and so is the immune system.
2. All Malaysians have been vaccinated against polio as children. Most people around the world have also been vaccinated against polio.And guess what, we still catch Covid19. If the polio vaccine had any protective ability, nobody is Asia, Africa and most of America would not have caught Covid19.
3. I have the correct training to professional call a stupid biomedical idea, idiotic..This is as idiotic as the people trying to see if the BCG vaccine works against Covid19, it doesn't!
Retail investors, AVOID Ho Wah Genting! Their attempt at using the polio vaccine as SARS-Cov2 vaccine will NEVER work.
Ho Wah Genting management if you are reading this, stop f-ing around. You are dragging the Genting name through the mud. You should be ashamed of yourselves!
If you want to make a vaccine against Covid19, do so properly. I know you are not a biotech company and don't have great technical experties, you are a cables and transportation company. So here is some general advice from someone who has worked at the NIH, make an inactivated viral vaccine. It isn't anymore difficult than growing the SARS-COv2 virus in cell culture, harvesting the virus, concentrating it either by ultracentrifugation or making a modified virus and purifying it on a binding column and inactivating the virus with formaldehyde. You can gamma irradiate for extra safety.
Seems bursamalaysia just a jaguh kampung... foreign investors mostly run away already, not confident with bursa because bursa now is the biggest casino in Malaysia taking over from Genting Malaysia !
KUALA LUMPUR: Foreign selling of local equities on Bursa Malaysia accelerated to RM937.5 million last week, from RM226.1 million in the preceding week, said MIDF Research.
In its weekly fund flow report today, MIDF Research said this was the 25th consecutive week of foreign net selling.
"So far in 2020, foreign investors have sold RM19.9 billion net on Bursa.
"In comparison with the other six Asian markets we track, Malaysia still has the fourth smallest foreign net outflow on a year-to-date basis," it added.
The firm said as the market reopened on Monday last week, foreign investors had disposed of RM174.1 million net of local equities, in spite of the Malaysia Leading Index (LI) rebounded to 0.6 per cent year-on-year (yoy) in May 20 from 5.7 per cent in the previous month.
This was the highest recorded LI since March 20 due to the reopening of economic activities after the movement control order (MCO).
"Foreign net outflow increased to RM250.9 million and RM336.9 million on Tuesday and Wednesday last week respectively with the largest net outflow of the week on Wednesday.
"The negative sentiments were probably due to the fear of a new wave of Covid-19 infections globally and deterioration of US-China relationship which might impede the recovery progress of the global economy as well as the uncertain domestic political scene," it said.
The net outflow subsided on Thursday at a tune of RM90.3 million, probably buoyed by the positive sentiments on another potential United States (US) stimulus package, better-than-expected US non farm payrolls of 1.76 million additional jobs in July and higher China's exports of 7.2 per cent yoy in July.
"On Friday, foreign net outflow was the lowest at RM85.3 million, coincided with the Malaysia's Industrial Production Index (IPI) which recorded a slower decline of 0.4 per cent yoy in June, mainly supported by the recovery in manufacturing output," it said.
MIDF Research said in comparison to another three Southeast Asian markets, Malaysia recorded the second highest foreign net outflow while Thailand experienced the least.
"In terms of participation, the retail investors recorded a weekly increase of 50.4 per cent in average daily traded value (ADTV) to RM8.4 billion.
"Meanwhile, the foreign investors experienced the least weekly increase in ADTV by 8.6 per cent to reach RM1.7 billion which was above the healthy level of RM1.0 billion," it added.
Page 1 of 4 MEMORANDUM OF AGREEMENT ENTERED INTO BETWEEN HWGB BIOTECH SDN BHD (“HWGB BIOTECH”) AND E-MO BIOLOGY INC. (“EBI”) Reference is made to the Company’s announcement released on 6 August 2020 on the Memorandum of Agreement between HWGB BIOTECH and EBI (“MOA”). Unless otherwise stated, abbreviations and definitions used throughout this announcement shall be the same as those previously defined in the previous announcement dated 6 August 2020 in relation to the MOA. The Company would like to provide the following additional information: 1. Paid- up share capital of EBI. As at 6 August 2020 EBI has no paid-up capital although there is an authorised shares of 1,000,000. 2. Background information such as educational, nationality and past working experiences of Qiyi Xie, Wei Chen, Lily Chen and Yan Wang. QiYi Xie is a citizen of People’s Republic of China, details of Qiyi Xie’s education and working experience are as follow: a) Educational: • MPH, Epidemiology & Bio-statistics, California State University, San Diego, California, United States of America; • Fellow, Bio-Chemistry, Molecular- biology, Beijing Medical University, Beijing, China, • Post-Doc Certificates, Chinese Academy of Preventive Medicine, • Microbiology, Infectious Diseases of Chinese Academy of Preventive Medicine • Medicine, Beijing Capital Medical University, Beijing, China b) Working experience: Over 30 years experiences in public health and infection disease control. More than 20 years of experience as an expert/specialized professional in medical and diagnostic devices with a focus on Quality, Regulatory and Clinical affairs under the Quality System. Former officer of national immunization program of China, WHO Fellow, CDC infectious diseases control specialists and epidemiologist, and multiple National, provincial, Academical reward recipients. With recent years as seasoned experts in the Clinical, Regulation and Law in global medical diagnostic device in supporting public health system at national and global healthcare markets. The Company is still in the midst of obtaining background information of Wei Chen, Lili Chen and Yan Wang. Page 2 of 4 3. Filing dates for all 5 PPA as well as the process & procedures, estimated time required to formalise the patent application. The filing dates for all 5 PPA are as follows: Application no. Inventor Description Filing date 63/008,664 Qiyi Xie, Wei Chen and Yan Wang A vaccine treatment for infectious diseases caused by Group IV viruses 11 April 2020 63/009,452 Qiyi Xie and Yan Wang A method for making vaccines against Group IV viruses 13 April 2020 63/010,678 Yan Wang, Qiyi Xie and Lili Chen A vaccine treatment for infectious diseases caused by Group IV viruses 15 April 2020 63/013,561 Qiyi Xie and Yan Wang A method for using an existing vaccine to treat and prevent infectious diseases caused by a novel virus 22 April 2020 63/014,711 Qiyi Xie and Yan Wang A method for treating an infectious disease by monoclonal antibodies 24 April 2020 The provisional patent applications were submitted to United States Patent and Trademark Office on submission dates mentioned in above table and the application will expire 12 months from date of filing. The final patent applications are expected to be filed prior to the expiry date of the provisional patent applications. 4. Further information on Group IV viruses and further elaboration on how the PPA will assist EBI in conducting the phase IV clinical trials referred to in item 5 below. The classification method created by Dr. David Baltimore, a Nobel Medicine Prize winner, categorizes all different viruses into Group I, II, III, IV, V, and VI depending upon the virus similarity in virus genomic setup and replication characterization as if they are in common. The group IV virus contains well known virus that cause human illness such as HIV, Corona virus, hepatitis A, and polymyositis virus. The current PPA specifically defines that in the Group IV virus not only they are in common of genomic (RNA) and replication method are the same, but also they co-shared the biological contents with significant similarities in both structure and functionality (transcriptase), such as the mechanism of cross reactivity in inducing immunity to the host. The later had not been described previously until EBI did as the COVID-19 occurred. This simply because it was only until now when the pandemic happened and the genome and structure of novel coronavirus-19 was known. From the timing point of view the inventors captured the relevancies and filed the PPA as the new discovery specifically for COVID-19, yet with some extents of coverage per the virus classification. Page 3 of 4 With the PPA, EBI is able to explain the reasons from the all gathered evidences of global epidemiological, etiological, human intervention of disease with vaccination, as well as from virus biological characteristics to demonstrate that why, and how COVID-19 become global pandemics.
Seems only naive small fish still believe this loh chin company
@mamatede
Ayo sign MOU and pay $1mil USD think can become vaccine player liao ah? Want to goreng up the stocks also do it properly la.
1. When you sign MOU like this and so obvious with 40% profit etc. This show u are an unethical company. 2. $1mil USD to secured the rights? Well thats because the company also dont even know their vaccine will succeed or not. Vaccine need billions to developt like J&J, Moderna, etc. 3. Any bulk purchase or vaccine will be by the government and company. Not individual company like this. Then government will assign local company for bottling and etc. Probably when everybody get their dose then small company like this Ho Wah will get a chance.
So, signing MOA only trap uncle and aunties to this unethical counter.
Eureka: Why do you think the oral polio vaccine is a good strategy against SARS-CoV-2?
Dr. Gallo: Let us start with Maurice Hilleman, who is arguably the most successful vaccinologist in history. Hilleman used to say that when you are making a vaccine, start with feasibility, ease of distribution and availability and safety. We have 70 years of experience with oral polio vaccine, and it has a tremendously safe record. Complications from oral polio have been zero in a vaccinated population, as the bulk of the world today is. We can easily produce it and there is plenty of evidence of surviving the cold chain. And large-scale clinical studies of oral polio vaccine against nonspecific prevention of disease, including in Russia, found that it was effective against influenza virus and genital herpes simplex virus.
Here’s the rationale. The oral polio vaccine – a weakened version of the live virus – is expected to trigger a general immune response to any foreign organism. During this time, the body will develop antibodies specific to the pathogen, such as the novel coronavirus, SARS-CoV-2. Researchers theorize that this temporary immune boost could confer a safeguard against viruses for which the vaccine wasn’t initially designed to defend against.
Here’s the rationale. The oral polio vaccine – a weakened version of the live virus – is expected to trigger a general immune response to any foreign organism. During this time, the body will develop antibodies specific to the pathogen, such as the novel coronavirus, SARS-CoV-2. Researchers theorize that this temporary immune boost could confer a safeguard against viruses for which the vaccine wasn’t initially designed to defend against.
There are advantages to using established vaccines, according to some experts.
“The benefit of redeploying existing therapies and vaccines that mechanistically show promise like the polio vaccine is that there is a track record of safety,” explains Nahid Bhadelia, MD, MALD, medical director of the Special Pathogens Unit, Boston Medical Center.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
tsohg
11 posts
Posted by tsohg > 2020-08-10 17:59 | Report Abuse
Dont have this E-MO Biology Inc (EBI) company detail at all, even website pun tak ada.